A potentially important mechanism for preventing future development of joint damage has been identified in a study of rheumatoid arthritis patients in Sweden.
Etanercept therapy down-regulates serum levels of matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis as well as the ratio between MMPs and their inhibitor, tissue inhibitor of matrix metalloproteinases (TIMP)-1.
The MMPs are cytokine-modulated enzymes that play a key role in the pathogenesis of rheumatoid arthritis (RA) by inducing bone resorption and cartilage destruction. To evaluate the modulation of serum and synovial MMPs and TIMP-1, A. I. Catrina and colleagues from the Departments of Rheumatology at Karolinska Hospital and Huddinge Hospital, Stockholm used therapy with soluble tumour necrosis factor (TNF)-a receptor (etanercept).
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!